TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25006120

Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine + volasertib (LDAC + volasertib)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDAC)
Number of subjects: 87
Study: 23271080

Group type: EXPERIMENTAL
Intervention: 1:1 PRBC/FFP transfusion strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4:1 PRBC/FFP transfusion strategy
Number of subjects: 0
Study: 19825870

Group type: EXPERIMENTAL
Intervention: Duplex ultrasound scanning (DUS)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Computed tomography angiography (CTA)
Number of subjects: 59
Study: 18072875

Group type: EXPERIMENTAL
Intervention: 1500 mg of calcium citrate daily (500 mg with meals)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 250 mg of calcium citrate daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dermal calcium loss during exercise
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lumbar spine BMD
Number of subjects: 14
Study: 16552324

Group type: EXPERIMENTAL
Intervention: Community-based screening for diabetes
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Community-based screening for hypertension
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Community-based screening for high cholesterol
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Community-based screening for high-risk individuals for diabetes
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Community-based screening for high-risk individuals for hypertension
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Community-based screening for high-risk individuals for total cholesterol
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Community-based screening for poorly controlled known diabetes
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Community-based screening for poorly controlled known hypertension
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Community-based screening for poorly controlled known high cholesterol
Number of subjects: 1757
Study: 12970287

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d (RLX60)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d (RLX120)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 10792117

Group type: EXPERIMENTAL
Intervention: Rifaximin, 1200 mg/day (400 mg t.d.s.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Chlortetracycline, 1 g/day (333 mg t.d.s.)
Number of subjects: 21
Study: 9240777

Group type: EXPERIMENTAL
Intervention: Postoperative mitomycin-C (0.04%) for 2 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin-C (0.04%) as a single dose
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (surgical excision only)
Number of subjects: 43
Study: 1467256

Group type: EXPERIMENTAL
Intervention: Cooperative learning in small groups
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Specially designed social relations programme
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Combination of social relations programme and cooperative learning
Number of subjects: 594

Group type: COMPARATOR
Intervention: Traditional pedagogical approaches (comparison group)
Number of subjects: 594
Study: 6647870

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 0
Study: 30774069

Group type: EXPERIMENTAL
Intervention: DRIFT (drainage, irrigation and fibrinolytic therapy)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard treatment (cerebrospinal fluid tapping)
Number of subjects: 52
Study: 27903837

Group type: EXPERIMENTAL
Intervention: New fighting vest designed for female body shape
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard special unit fighting vest
Number of subjects: 240
Study: 26116011

Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 67
Study: 23530976

Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised lower limb muscle strengthening exercises for 10 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: No exercises (control)
Number of subjects: 17
Study: 21774100

Group type: EXPERIMENTAL
Intervention: Multimodal intervention (patient education, home BP monitoring, BP measurement reporting to an IVR system, clinical pharmacist follow-up)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 338
Study: 19260949

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of simvastatin and bezafibrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control subjects (49 non-diabetic)
Number of subjects: 14
Study: 16440534

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study: 15268810

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg once daily for 52 weeks
Number of subjects: 105
Study: 11577896

Group type: EXPERIMENTAL
Intervention: Wavelet analysis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fourier analysis
Number of subjects: 40
Study: 10434907

Group type: EXPERIMENTAL
Intervention: Quantitative analysis of enhancement patterns using T1 weighted spoiled gradient recalled echo (SPGR) images during bolus intravenous injection of 0.1 mmol kg‐1 of Gd‐chelate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Computer assisted analysis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Manual measurements of maximum enhancement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Measurement of maximum enhancement alone
Number of subjects: 32
Study: 7805462

Group type: EXPERIMENTAL
Intervention: Captopril plus spironolactone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 35
Study: 3292516

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31340917

Group type: EXPERIMENTAL
Intervention: Local infiltration of ropivacaine combined with multimodal analgesia with parecoxib
Number of subjects: 98

Group type: COMPARATOR
Intervention: Postoperative analgesia with dizosin
Number of subjects: 98
Study: 27942734

Group type: EXPERIMENTAL
Intervention: Intervention group (N=354) with reduced worktime to 75% for 18 months
Number of subjects: 580

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 580
Study: 26058988

Group type: EXPERIMENTAL
Intervention: Screening for silent myocardial ischemia followed by revascularization
Number of subjects: 520

Group type: COMPARATOR
Intervention: Follow-up without screening
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Older than 60 years
Number of subjects: 520
Study: 22820124

Group type: EXPERIMENTAL
Intervention: Walking condition
Number of subjects: 179

Group type: COMPARATOR
Intervention: Flexibility, toning, and balance condition
Number of subjects: 179
Study: 22186072

Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulphonamide treatment for 3 months followed by Fansidar(®) for 9 months
Number of subjects: 486

Group type: COMPARATOR
Intervention: Therapeutic abstention
Number of subjects: 486
Study: 19154810

Group type: EXPERIMENTAL
Intervention: Rapid Folin-Ciocalteu method using Oasis MAX 96-well plate cartridges for solid phase extraction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cross-sectional study
Number of subjects: 60
Study: 16319099

Group type: EXPERIMENTAL
Intervention: Hand-strengthening and mobilizing home exercises (Group 1)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Hand-stretching exercises (Group 2)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Joint protection information alone (Group 3)
Number of subjects: 67
Study: 15479589

Group type: EXPERIMENTAL
Intervention: Implantable gastric stimulation (IGS) activated group
Number of subjects: 133

Group type: COMPARATOR
Intervention: Implantable gastric stimulation (IGS) non-activated group
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: DIGEST trial with IGS
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Selected patients with preoperative screening algorithm
Number of subjects: 133
Study: 11049014

Group type: EXPERIMENTAL
Intervention: Prescribed drugs
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Over-the-counter (OTC) drugs
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Central nervous system (CNS) drugs
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: OTC drugs
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Potential drug interactions
Number of subjects: 492
Study: 9052345

Group type: EXPERIMENTAL
Intervention: Enalapril (5 or 20 mg) and Felodipine ER (2.5, 5, or 10 mg)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Felodipine ER monotherapy
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Enalapril-Felodipine ER combinations
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg) and Felodipine ER (10 mg)
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg) and Felodipine ER (2.5 mg)
Number of subjects: 707
Study: 8305650

Group type: EXPERIMENTAL
Intervention: Two levels of blood pressure control and two dietary interventions
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Dietary control of protein and phosphorus
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Study A and Study B
Number of subjects: 840
Study: 3329515

Group type: EXPERIMENTAL
Intervention: 2 mg benzhexol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 29472432

Group type: EXPERIMENTAL
Intervention: Fenofibrate treatment
Number of subjects: 17142
Study: 27070250

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) treatment for 2 weeks, 14-minute sessions
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) treatment
Number of subjects: 11
Study: 25023033

Group type: EXPERIMENTAL
Intervention: Sequential rescue therapies
Number of subjects: 0
Study: 22230827

Group type: COMPARATOR
Intervention: escitalopram plus placebo
Number of subjects: 665

Group type: COMPARATOR
Intervention: bupropion-SR plus escitalopram
Number of subjects: 665

Group type: COMPARATOR
Intervention: venlafaxine-XR plus mirtazapine
Number of subjects: 665
Study: 20001574

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 2652

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 2652
Study: 18710676

Group type: EXPERIMENTAL
Intervention: Self-reported smoking in the previous 30 days
Number of subjects: 2209

Group type: EXPERIMENTAL
Intervention: Self-reported daily smoking
Number of subjects: 2209

Group type: COMPARATOR
Intervention: Cotinine concentration cutoff of 10 ng/mL
Number of subjects: 2209

Group type: COMPARATOR
Intervention: Cotinine concentration cutoff of 30 ng/mL
Number of subjects: 2209
Study: 17221005

Group type: EXPERIMENTAL
Intervention: Surgery with preoperative planning using neuroimaging, anatomical study, microsurgery technique, and cortical stimulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cortical stimulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Stereotaxy method
Number of subjects: 42
Study: 12891299

Group type: EXPERIMENTAL
Intervention: simvastatin (10‐20 mg/day), clopidogrel (75 mg/day), and trimetazidine (60 mg/day) for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: simvastatin and clopidogrel for 6 months
Number of subjects: 42
Study: 11146601

Group type: EXPERIMENTAL
Intervention: Anti epileptic medication
Number of subjects: 76

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Normal EEG
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Abnormal EEG
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Family history of seizure
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Duration of seizure at initial presentation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Time since first seizure
Number of subjects: 76
Study: 8858649

Group type: EXPERIMENTAL
Intervention: Nebulizer treatment group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MDI-spacer treatment group 1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MDI-spacer treatment group 2
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of all groups
Number of subjects: 60
Study: 7961241

Group type: EXPERIMENTAL
Intervention: OSL training with audiovisual feedback; 15 treadmill sessions (30 min/day, 5 days/wk, 3 wk) at velocities of 2.87-3.74 m/s.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group performing treadmill running without feedback for 3 weeks.
Number of subjects: 12
Study: 3300424

Group type: EXPERIMENTAL
Intervention: Epidural ketamine (4, 6, and 8 mg in saline; 6 mg in 10% glucose)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Epidural morphine (3 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 68
Study: 28962912

Group type: EXPERIMENTAL
Intervention: Lumbar transforaminal epidural steroid injections (TFESIs)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 78
Study: 27866386

Group type: EXPERIMENTAL
Intervention: Handwashing with soap and water plus hand sanitizer (Experimental Group)
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Usual handwashing procedures (Control Group)
Number of subjects: 1341
Study: 25596171

Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Paracervical infiltration with 1% lidocaine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 106
Study: 23997095

Group type: EXPERIMENTAL
Intervention: PEMI after sublingual administration of 5 mg of isosorbide dinitrate (ISDN)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control exercise recovery (CER) session
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PEMI session
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CER after ISDN
Number of subjects: 10
Study: 21261949

Group type: EXPERIMENTAL
Intervention: Liverpool Care Pathway for the dying patient (LCP-I) Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study: 18507819

Group type: EXPERIMENTAL
Intervention: Stamped addressed envelopes
Number of subjects: 477

Group type: COMPARATOR
Intervention: Pre-paid business reply envelopes
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Cost per returned item for stamped envelopes
Number of subjects: 477

Group type: COMPARATOR
Intervention: Cost per returned item for pre-paid envelopes
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Cost comparison excluding set up cost for pre-paid service
Number of subjects: 477
Study: 16583466

Group type: EXPERIMENTAL
Intervention: Single SC doses of 0.5, 1.5, or 3.0 mg/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: SC doses of 100 mg every 2 weeks (3 injections)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 3 mg/kg IV infliximab every 2 weeks (2 infusions) followed by 100 mg SC every 2 weeks (3 injections)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 100 mg IM every 2 weeks (3 injections)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 100 mg SC every 4 weeks (3 injections)
Number of subjects: 43
Study: 14726973

Group type: EXPERIMENTAL
Intervention: Radiofrequency fistulotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional fistulotomy
Number of subjects: 50
Study: 11075846

Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Citalopram 20 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 7830026

Group type: EXPERIMENTAL
Intervention: Comprehensive, multiple-risk factor modification programme
Number of subjects: 508

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 508
Study: 1978660

Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 354733

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorpromazine and Amitriptyline (both)
Number of subjects: 60
Study: 30068245

Group type: EXPERIMENTAL
Intervention: GOAL intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 30945515

Group type: EXPERIMENTAL
Intervention: Intermittent automatic bolus (N=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Continuous infusion (N=40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 28760205

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy with edoxaban
Number of subjects: 3400

Group type: COMPARATOR
Intervention: No anticoagulation (control group)
Number of subjects: 3400

Group type: COMPARATOR
Intervention: Aspirin or no antithrombotic therapy (control group)
Number of subjects: 3400
Study: 25650159

Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate (MF)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 23186831

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 21592754

Group type: EXPERIMENTAL
Intervention: RS + WBRT
Number of subjects: 21

Group type: COMPARATOR
Intervention: S + WBRT
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 21
Study: 19351223

Group type: EXPERIMENTAL
Intervention: Aceclofenac-paracetamol combination (100 mg aceclofenac + 500 mg paracetamol bid)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Aceclofenac alone (100 mg bid)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Aceclofenac-paracetamol combination
Number of subjects: 199

Group type: COMPARATOR
Intervention: Aceclofenac alone
Number of subjects: 199
Study: 17032347

Group type: EXPERIMENTAL
Intervention: Product of insulin sensitivity and insulin secretion (B-beta)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Product B-beta
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Cut-off point for product B-beta
Number of subjects: 375
Study: 14676562

Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sevoflurane/nitrous oxide/fentanyl anesthesia
Number of subjects: 20
Study: 11444253

Group type: EXPERIMENTAL
Intervention: docetaxel 100 mg/m2
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m2
Number of subjects: 577

Group type: COMPARATOR
Intervention: BSC
Number of subjects: 577

Group type: COMPARATOR
Intervention: vinorelbine 30 mg/m2 or ifosfamide 2 g/m2
Number of subjects: 577
Study: 9136776

Group type: EXPERIMENTAL
Intervention: Pylorus-preserving Whipple (PPW)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Duodenum-preserving pancreatic head resection (DPPHR)
Number of subjects: 20
Study: 8053664

Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor (rhNGF) intravenous or subcutaneous doses ranging from 0.03 to 1 micrograms/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor (rhNGF) at doses above 0.1 microgram/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor (rhNGF) subcutaneous doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human nerve growth factor (rhNGF) intravenous doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 2970218

Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate plus mitomycin-C (MMC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-dose medroxyprogesterone acetate plus vindesine
Number of subjects: 40
Study: 31674161

Group type: EXPERIMENTAL
Intervention: Neurofeedback augmentation group (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Medication-only (treatment as usual [TAU] group, n = 12)
Number of subjects: 24
Study: 28857958

Group type: EXPERIMENTAL
Intervention: CCLS present during procedure (Group I)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No CCLS present during procedure (Group II)
Number of subjects: 86
Study: 26099838

Group type: EXPERIMENTAL
Intervention: 3 Dp
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3D
Number of subjects: 120

Group type: COMPARATOR
Intervention: CT
Number of subjects: 120
Study: 23024159

Group type: EXPERIMENTAL
Intervention: Nurse management arm
Number of subjects: 288

Group type: COMPARATOR
Intervention: Feedback approach
Number of subjects: 288
Study: 21218023

Group type: EXPERIMENTAL
Intervention: Brief individual intervention focusing on insight enhancement (5 sessions)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (identical treatment program without insight enhancement)
Number of subjects: 41
Study: 19110596

Group type: EXPERIMENTAL
Intervention: Granulocytic CSF (neupogen) added to chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (adriablastine+taxotere) without neupogen
Number of subjects: 0
Study: 16860622

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and plication (RAMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional ligature and excision procedure (LEP)
Number of subjects: 0
Study: 12905096

Group type: COMPARATOR
Intervention: Continuous exercise (CON) - walking at 60 to 75% of maximum aerobic capacity, 3 days per week, 30 minutes per session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent exercise (INT) - two 15-minute sessions, 5 days per week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (CON and INT)
Number of subjects: 0